Agios Pharmaceuticals (AGIO) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Agios Pharmaceuticals (AGIO) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 9.4% versus a loss of 50.9%. Over five years, AGIO leads with a -24.3% price change compared with -78.5% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.68 billion vs $1.65 billion), about 1.0 times the size, while Agios Pharmaceuticals is growing revenue faster (+48.0% vs +20.2%).
Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -764.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | RARE |
|---|---|---|
| Share price | $27.60 | $16.48 |
| Market cap | $1.65B | $1.68B |
| 1-day change | -4.03% | -4.30% |
| YTD return | +1.40% | -28.35% |
| 1-year return | +9.35% | -50.94% |
| 5-year return | -24.28% | -78.45% |
| Forward P/E | — | 11.50 |
| EPS (TTM) | $-6.31 | $-5.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $54.03M | $673.00M |
| Revenue growth (YoY) | +48.03% | +20.18% |
| Net income (latest FY) | $-412.78M | $-575.00M |
| Gross margin | 88.26% | — |
| Operating margin | -873.87% | -79.49% |
| Net margin | -764.01% | -85.44% |
| 52-week high | $44.09 | $39.89 |
| 52-week low | $24.16 | $12.73 |
| Distance from 52-week high | -37.40% | -58.69% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +67.07% | +50.49% |
| Average volume | 1.06M | 4.69M |
| Shares outstanding | 59.81M | 101.92M |
| Employees | 539 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGIO has outperformed RARE by 60.3 percentage points over the past year.
- Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
- Agios Pharmaceuticals grew revenue faster in its latest fiscal year (+48.03% vs +20.18%).
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
AGIO vs RARE FAQ
Which is bigger, Agios Pharmaceuticals or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.68B compared with $1.65B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or RARE?
AGIO returned +9.35% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.